Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

FBRX vs LCTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

FBRX Captures Overall Composite Edge (52.7 HOLD vs 54.9 HOLD), While LCTX Leads 3–2 on Growth & Valuation Pillars

FBRX Overall Winner 6-Pillar Tally: FBRX 2 – 3 LCTX (1 Tie) Matrix Metrics: FBRX 5 – 5 LCTX

As of Nov 20, 2026, Forte Biosciences, Inc. (FBRX) captures the overall head-to-head institutional edge over Lineage Cell Therapeutics, Inc. (LCTX) on higher Unified Composite conviction (52.7/100 HOLD vs. 54.9/100 HOLD) after splitting the core matrix 5–5 (led by Growth & Scale, Options & Positioning), while LCTX wins 3–2 across the 6-pillar growth and valuation breakdown. FBRX trades at $76.99 (N/M Forward P/E, 0.0% operating margin) versus LCTX at $0.77 (30.7x Forward P/E, -280.3% operating margin).

  • Composite vs. Pillar Nuance: While LCTX currently prints a higher short-term Unified Composite Score (54.9/100 HOLD vs. FBRX 52.7/100 HOLD), FBRX captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -280.3% operating margin) and revenue trajectory (+0.0% vs. -61.0% YoY).
  • Technical & Structure Timing Caution: FBRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 84.7); meanwhile LCTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FBRX vs LCTX
FBRX NASDAQ Head-to-Head Winner
Forte Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$76.99
+0.03% 1D
Market Cap $1.6B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.09β · 3% Vol
Unified Composite Score
52.7 / 100 HOLD
Tech 49.0 Fund 51.0 Flow 62.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (78.3% over 20 days), RSI 85
RSI-14: 84.7 · SMA20: $76.83 · SMA50: $52.74
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.77
-5.87% 1D
Market Cap $207.4M
TTM Revenue $11M
Forward P/E 30.7x
Beta / 30D Vol 1.39β · 79% Vol
Unified Composite Score
54.9 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 72.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.6%), weak momentum, RSI 34
RSI-14: 34.1 · SMA20: $0.97 · SMA50: $0.97

6-Pillar Scorecard Institutional Category Breakdown (FBRX 2 – 3 LCTX)

Columns: Metric · FBRX · LCTX
1. Valuation Multiples LCTX
Forward P/E N/M 30.7x
Trailing P/E N/M 30.7x
PEG Ratio N/M 10.64x
EV / Revenue N/M 15.9x
2. Growth & Scale FBRX
Revenue Growth (YoY) +0.0% -61.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $11M
Market Cap $1.6B $207.4M
3. Profitability & Quality LCTX
Gross Margin N/A -95.0%
Operating Margin 0.0% -280.3%
Net Profit Margin 0.0% 16.2%
Return on Equity (ROE) -62.3% 4.3%
4. Balance Sheet & Cash Flow LCTX
Cash Generation (TTM) -$72M -$24M
Cash Flow Margin N/A N/A
Net Cash / Leverage $7.52 Book/Sh · -62.3% ROE $35M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning FBRX
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 11.1% (3rd %ile) 0.0% (<1st %ile)
Put/Call OI Skew 0.77x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FBRX (5) vs LCTX (5)
Institutional Metric FBRX LCTX Criterion Row Edge
Market Capitalization
Scale
$1.6B $207.4M Larger Scale FBRX
Trailing P/E Ratio
Valuation
N/M 30.7x Lower Multiple LCTX
Forward P/E Ratio
Valuation
N/M 30.7x Lower Multiple LCTX
Revenue Growth (YoY)
Growth
+0.0% -61.0% Higher Growth FBRX
Operating Margin (TTM)
Profitability
0.0% -280.3% Higher Margin FBRX
Net Profit Margin
Profitability
0.0% 16.2% Higher Margin LCTX
Return on Equity (ROE)
Capital Efficiency
-62.3% 4.3% Higher ROE LCTX
52-Week Range Position
Momentum
100% ($10–$77) 0% ($1–$2) Stronger Trend FBRX
Beta / 30D Volatility
Risk Regime
1.09β · 3% Vol 1.39β · 79% Vol Lower Realized Risk FBRX
Unified Institutional Score
Composite Signal
52.7 / 100 (HOLD) 54.9 / 100 (HOLD) Higher Composite LCTX
Trailing 12M Revenue (USD)
Operating Scale
N/A $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -95.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 10.64x PEG · 15.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$72M ($7.52 Book/Sh · -62.3% ROE) -$24M ($35M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LCTX +4.23 pp
FBRX: +0.44% · LCTX: +4.67%
3M Horizon FBRX +272.44 pp
FBRX: +258.59% · LCTX: -13.85%
6M Horizon FBRX +211.76 pp
FBRX: +170.71% · LCTX: -41.05%
1Y Horizon FBRX +345.99 pp
FBRX: +311.49% · LCTX: -34.5%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period FBRX Revenue LCTX Revenue FBRX Op. Margin LCTX Op. Margin Margin Leader
FY2018 $20M $0M -254.2% -837.9% FBRX
FY2019 $0M $0M -11288.9% -1106.0% LCTX
FY2020 N/A $0M N/A -1448.4% LCTX
FY2021 N/A $0M N/A -1133.6% LCTX
FY2022 N/A $10M N/A -153.2% LCTX
FY2023 N/A $10M N/A -276.5% LCTX
FY2024 N/A $10M N/A -226.1% LCTX
FY2025 N/A $10M N/A -251.6% LCTX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FBRX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 11.1%
IV Percentile 3rd %ile
Put/Call OI Skew 0.77x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact FBRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LCTX BREAKDOWN
7d in phase · OBV DISTRIBUTION
Current IV 0.0%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact LCTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FBRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.6B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LCTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $207.4M market capitalization and -280.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ FBRX vs LCTX Key Questions & Quantitative Answers

As of Nov 20, 2026, Forte Biosciences, Inc. (FBRX) captures the overall head-to-head institutional edge over Lineage Cell Therapeutics, Inc. (LCTX) on higher Unified Composite conviction (52.7/100 HOLD vs. 54.9/100 HOLD) after splitting the core matrix 5–5 (led by Growth & Scale, Options & Positioning), while LCTX wins 3–2 across the 6-pillar growth and valuation breakdown. FBRX trades at $76.99 (N/M Forward P/E, 0.0% operating margin) versus LCTX at $0.77 (30.7x Forward P/E, -280.3% operating margin). Composite vs. Pillar Nuance: While LCTX currently prints a higher short-term Unified Composite Score (54.9/100 HOLD vs. FBRX 52.7/100 HOLD), FBRX captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -280.3% operating margin) and revenue trajectory (+0.0% vs. -61.0% YoY). Technical & Structure Timing Caution: FBRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 84.7); meanwhile LCTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FBRX leads the Growth & Scale pillar: FBRX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with LCTX at -61.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (-95.0% gross margin, -280.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), FBRX cumulative revenue shifted N/A while LCTX shifted +0.0%. In operating R&D and SG&A reinvestment, FBRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LCTX.

LCTX screens cheaper on headline valuation multiples. FBRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas LCTX trades at 30.7x Forward P/E, 30.7x Trailing P/E, 10.64x PEG, and 15.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FBRX (-62.3% ROE) versus LCTX (4.3% ROE) capital efficiency.

In options market volatility and institutional positioning, FBRX carries 11.1% implied volatility (3rd %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.09β · 3% Vol realized risk). By comparison, LCTX carries 0.0% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.39β · 79% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.